TBCRC 008: Early Change in ^sup 18^F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer

Epigenetic modifiers, including the histone deacetylase inhibitor vorinostat, may sensitize tumors to chemotherapy and enhance outcomes. We conducted a multicenter randomized phase II neoadjuvant trial of carboplatin and nanoparticle albumin-bound paclitaxel (CP) with vorinostat or placebo in women...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The Journal of nuclear medicine (1978) 2015-01, Vol.56 (1), p.31
Hauptverfasser:	Connolly, Roisin M, Leal, Jeffrey P, Goetz, Matthew P, Zhang, Zhe, Zhou, Xian C, Jacobs, Lisa K, Mhlanga, Joyce, Joo, H O, Carpenter, John, Storniolo, Anna Maria, Watkins, Stanley, Fetting, John H, Miller, Robert S, Sideras, Kostandinos, Jeter, Stacie C, Walsh, Bridget, Powers, Penny, Zorzi, Jane, Boughey, Judy C, Davidson, Nancy E, Carey, Lisa A, Wolff, Antonio C, Khouri, Nagi, Gabrielson, Edward, Wahl, Richard L, Stearns, Vered
Format:	Artikel
Sprache:	eng
Schlagworte:	Breast cancer Chemotherapy Correlation analysis Epidermal growth factor Epigenetics Nanoparticles Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!